Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
Phase 1
Completed
NCT00591214
| Condition | Chronic Hepatitis C |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | Tanabe Pharma Corporation |
|---|
| Status | Completed |
|---|
| Enrollment | 10 participants |
|---|
| Interventions | MP-424 (Telaprevir) |
|---|
| Start date | Dec, 2007 |
|---|
| Completion date | Oct, 2008 |
|---|
| Results posted | Oct 22, 2012 |
|---|
Summary
The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.
Cmax (Maximum Observed Concentration in Plasma) of MP-424
Date were collected at Day1 to Day85 · μg / mL
| MP-424 | 2.24 ± 0.93 μg / mL |
|---|
| MP-424 | 3.34 ± 1.11 μg / mL |
|---|
| MP-424 | 3.68 ± 1.29 μg / mL |
|---|
Tmax (Time of Maximum Plasma Concentration) of MP-424
Date were collected at Day1 to Day85 · hours
| MP-424 | 2.50 hours |
|---|
| MP-424 | 2.49 hours |
|---|
| MP-424 | 2.72 hours |
|---|
AUC 0-8h (Area Under the Concentration-time Curve From Time Zero to 8 Hours) of MP-424
Date were collected at Day1 to Day85 · μg x h /mL
| MP-424 | 11.60 ± 4.74 μg x h /mL |
|---|
| MP-424 | 22.31 ± 8.29 μg x h /mL |
|---|
| MP-424 | 23.98 ± 9.45 μg x h /mL |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.